Description: ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases.
Home Page: www.zyversa.com
ZVSA Technical Analysis
2200 N. Commerce Parkway
Weston,
FL
33326
United States
Phone:
754 231 1688
Officers
| Name | Title |
|---|---|
| Mr. Stephen C. Glover | Co-Founder, Chairman, CEO & President |
| Mr. Peter Wolfe | CFO & Secretary |
| Ms. Karen A. Cashmere | Chief Commercial Officer |
| Ms. Melda Uzbil O'connell | Senior Vice President of Corporate Development |
| Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0022 |
| Price-to-Book MRQ: | 0.3603 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-12-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |